According to one of the latest study appeared in the Journal of Arthritis & Rheumatol, Vertebral fractures and high FN‐BMD are the prognostic risk factors of knee/hip radiographic osteoarthritis (ROA) and incident hand ROA, respectively. A total of 4,154 individuals were selected to evaluate 1) the association between widespread vertebral and non‐vertebral fractures and the rate and growth of osteoarthritis in older men and women in the Rotterdam Study, and 2) the longitudinal connection between bone mineral density (BMD) and the prevalence and acceleration of the hand, hip, and knee osteoarthritis.
The Rheumatoid arthritis patients experienced high falls rate, mostly affected by disease-related outcomes, as reported by the researchers of University of Campinas, Brazil. However, a steeper fall rate noticed among the patients who suffered from RA, but the studies comprising information about falls and its association with clinical data, disease-related results and physical performance tests showed a substantial inequality and therefore to validate the report this study was conducted.
As per a report of investigators of Rehabilitation Medicine, University of Alberta adults with a sport-related knee injury shows more adverse health-associated outcomes with constant with osteoarthritis risk. As the active youth are exposed to more knee injuries, and consequent osteoarthritis, enhanced knowledge regarding the relationship between the history of joint injury and the health-related outcomes could notify osteoarthritis prevention approaches.
According to the findings of a Multicenter Osteoarthritis Study, the varus thrust is considered as one of the major risk factors for aggravating and incident knee pain. The presence of varus thrust at baseline was assessed using the video recordings of self‐paced walking trials of Multicenter Osteoarthritis Study (MOST) participants.
As per a recent open‐label multicenter clinical analysis published in the Journal of Obstetrics and Gynaecology Research, Dydrogesterone, a retro‐progesterone emerges as an effective treatment for dysmenorrhea.
A total of 31and 44 patients were selected for efficacy and safety analysis, respectively. Patients received one oral Dydrogesterone 5‐mg tablet twice daily for 21 days from 5th to 25th day of the menstrual cycle.
- 1 of 255